Analysts take a look at Amedisys, Inc. (NASDAQ:AMED) having this to say.

Amedisys, Inc. (NASDAQ:AMED) Logo
Investors sentiment decreased to 1.03 in Q2 2019. Its down 0.03, from 1.06 in 2019Q1. It turned negative, as 44 investors sold Amedisys, Inc. shares while 81 reduced holdings. 47 funds opened positions while 82 raised stakes. 26.15 million shares or 1.54% less from 26.55 million shares in 2019Q1 were reported.
Rothschild & Asset Management Us holds 0.44% or 339,200 shares. Gemmer Asset Management Limited Com accumulated 0% or 20 shares. Redmile Grp Incorporated Ltd Liability Company invested in 2,320 shares. Moreover, Blair William & Company Il has 0.01% invested in Amedisys, Inc. (NASDAQ:AMED). Kansas-based Creative Planning has invested 0% in Amedisys, Inc. (NASDAQ:AMED). Sterling Cap Ltd reported 12,924 shares. Sg Americas Secs Limited Liability Corp reported 0.01% in Amedisys, Inc. (NASDAQ:AMED). Credit Suisse Ag accumulated 28,410 shares. Apg Asset Mgmt Nv, a Netherlands-based fund reported 231,000 shares. Columbus Circle Investors has 80,904 shares. 25,728 are held by Mutual Of America Cap Mngmt Ltd Llc. Moreover, Goldman Sachs Inc has 0% invested in Amedisys, Inc. (NASDAQ:AMED). Aperio Limited Liability reported 24,392 shares. 5,294 are owned by Pub Employees Retirement Association Of Colorado. Bancshares Of New York Mellon holds 0.02% or 545,492 shares.

Amedisys, Inc. (NASDAQ:AMED) Ratings Coverage

Among 3 analysts covering Amedisys (NASDAQ:AMED), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Amedisys has $145 highest and $120 lowest target. $138’s average target is 3.95% above currents $132.75 stock price. Amedisys had 7 analyst reports since March 19, 2019 according to SRatingsIntel. The stock has “Outperform” rating by Raymond James on Thursday, May 2. The stock of Amedisys, Inc. (NASDAQ:AMED) has “Buy” rating given on Thursday, March 21 by SunTrust. As per Monday, July 15, the company rating was maintained by Raymond James. Barclays Capital maintained it with “Equal-Weight” rating and $120 target in Thursday, March 21 report. Barclays Capital maintained it with “Equal-Weight” rating and $12500 target in Monday, August 5 report. Below is a list of Amedisys, Inc. (NASDAQ:AMED) latest ratings and price target changes.

05/08/2019 Broker: Barclays Capital Rating: Equal-Weight Old Target: $120.0000 New Target: $125.0000 Maintain
15/07/2019 Broker: Raymond James Rating: Outperform Old Target: $140.0000 New Target: $144.0000 Maintain
06/06/2019 Broker: BidaskScore Rating: Hold Upgrade
02/05/2019 Broker: Raymond James Old Rating: Market Perform New Rating: Outperform New Target: $140.0000 Upgrade
21/03/2019 Broker: SunTrust Rating: Buy New Target: $145 Maintain
21/03/2019 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $115 New Target: $120 Maintain
19/03/2019 Broker: Oppenheimer Rating: Buy Maintain

The stock increased 0.84% or $1.1 during the last trading session, reaching $132.75. About 207,498 shares traded. Amedisys, Inc. (NASDAQ:AMED) has risen 47.57% since September 13, 2018 and is uptrending. It has outperformed by 47.57% the S&P500.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The company has market cap of $4.27 billion. It operates through three divisions: Home Health, Hospice, and Personal Care. It has a 35.2 P/E ratio. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

More notable recent Amedisys, Inc. (NASDAQ:AMED) news were published by: which released: “Edwards Lifesciences Sapien 3 System Recall Classified Class I – Nasdaq” on August 23, 2019, also with their article: “Here’s Why You Should Hold on to Ecolab (ECL) Stock Now – Nasdaq” published on September 12, 2019, published: “Here’s Why You Should Hold on to ResMed (RMD) Stock for Now – Nasdaq” on August 28, 2019. More interesting news about Amedisys, Inc. (NASDAQ:AMED) were released by: and their article: “Here’s Why You Should Retain Bio-Rad (BIO) Stock for Now – Nasdaq” published on August 23, 2019 as well as‘s news article titled: “Here’s Why You Should Invest in Intuitive Surgical (ISRG) Now – Nasdaq” with publication date: September 10, 2019.

Amedisys, Inc. (NASDAQ:AMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.